BMS pushes BMS-986470 sickle cell readout 480 days as enrollment target grows 22%
Bristol-Myers Squibb's early-stage HbF-inducer trial now completes April 2028, not January 2027, alongside a jump from 184 to 224 participants and a safety-primary design that will not settle efficacy.
Executive Summary
- Bristol-Myers Squibb pushed the primary completion date for its Phase 1/2 BMS-986470 sickle cell trial from January 6, 2027 to April 30, 2028, a cumulative delay of 480 days, while enrollment guidance rose from 184 to 224 participants Press Release+1Press ReleaseJul 6, 2026A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseNCT06481306. That combination points to a trial expanding in scope, not just slipping on execution.
- The trial's primary endpoints are almost entirely safety-focused, tracking deaths, adverse events, and dose-limiting toxicities, alongside proportion of participants reaching fetal hemoglobin thresholds of 10%, 20%, and 30%. That design means the 2028 readout will speak to tolerability and biomarker response, not to a registrational efficacy claim.
- AppliedXL's model puts the probability this trial's endpoint clears at 34.0% and its clinical significance read at 37.8%, both computed as of June 2024 and unchanged since NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseNCT06481306. The read leans on the sickle cell therapeutic area's historical success rate rather than mechanism-specific evidence, since BMS-986470's target is undisclosed.
- The trial sits inside a sickle cell disease field with at least six named small-molecule competitors in Phase 2 or Phase 3, including Pfizer's voxelotor and osivelotor and Novo Nordisk's etavopivat, none of which share BMS-986470's undisclosed target. No head-to-head or same-drug competition exists for BMS-986470 itself.
- No results have posted to ClinicalTrials.gov, and BMS-986470's molecular target and mechanism of action remain unclassified in AppliedXL's taxonomy. That leaves the story anchored to timeline and design facts rather than any disclosed clinical outcome.
The timing shift
ClinicalTrials.gov records for NCT06481306 show Bristol-Myers Squibb moved the study's primary completion date from January 6, 2027 to April 30, 2028 on July 6, 2026, a cumulative delay of 480 days from the trial's original guidance Press Release+1Press ReleaseJul 6, 2026A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseNCT06481306. The same update raised the enrollment target from 184 to 224 participants, a 21.7% increase. AppliedXL's protocol-stability tool logged two eligibility criteria amendments alongside the enrollment change, a combination it flags as a potential population shift rather than a simple timeline slip.
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial can prove
The study enrolls healthy volunteers in Cohort A and sickle cell disease patients with documented HbSS, HbSβ0-thal, or HbSβ+-thal genotypes and a history of vaso-occlusive crises in Cohort B. Its primary endpoints are safety measures, deaths, adverse events, serious adverse events, and dose-limiting toxicities, tracked over 26 months, plus the proportion of patients reaching fetal hemoglobin (HbF) thresholds of 10%, 20%, and 30% within 28 days of the last dose. This is an open, non-registrational Phase 1/2 design without a placebo comparator arm, so the 2028 readout will establish safety and early biomarker signal, not a confirmed efficacy claim.
The model's basis
AppliedXL's model puts the probability this trial's endpoint is met at 34.0% and rates its overall clinical significance at 37.8%, both figures dated to the trial's first registry submission in June 2024 and unchanged since NCT06481306A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseNCT06481306. The largest driver behind that number is the sickle cell disease therapeutic area's historical success rate (a structural, indication-level statistic), not a mechanism-specific signal, since BMS-986470's molecular target has not been disclosed in the registry. A read built mainly on an indication base rate, absent mechanism data, warrants lower confidence than one grounded in target validation or clinical precedent.
Where it sits competitively
The sickle cell disease pipeline includes at least six named small-molecule competitors, Pfizer's voxelotor and osivelotor, Novo Nordisk's etavopivat, Agios's mitapivat and tebapivat, and Fulcrum's pociredir, all in Phase 2 or Phase 3 and all targeting different mechanisms (hemoglobin polymerization, pyruvate kinase activation, or BCL11A). None qualifies as a direct comparator to BMS-986470 because its own target is undisclosed, and AppliedXL's competitive model finds no eligible direct comparator or same-drug competition for this program.
Operational context
AppliedXL's risk model scores NCT06481306 at elevated risk (70 of 100), driven by the cumulative 480-day delay, the enrollment increase, and the paired eligibility amendments. Sponsor-wide, Bristol-Myers Squibb has completed 925 of 1,044 tracked trials, an 89% overall completion rate, so the delay here does not reflect a broader pattern of program abandonment at the company level.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.